Generic Name and Formulations:
Mesna 400mg; tabs.
Indications for MESNEX:
Prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis.
See literature. IV Schedule: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration and 4 and 8 hours after each dose of ifosfamide; total daily dose is 60% the ifosfamide dose. IV and oral dosing: Give as IV bolus injection in a dosage equal to 20% of the ifosfamide dose at the time of ifosfamide administration, followed by the tablets given orally in a dosage equal to 40% of the ifosfamide dose 2 and 6 hours after each dose of ifosfamide; total daily dose is 100% of the ifosfamide dose. Repeat schedule on each day ifosfamide is given. If vomiting occurs within 2hrs of oral mesna, repeat dose or give IV mesna.
Hypersensitivity to thiol compounds.
Monitor morning specimen of urine for the presence of hematuria each day prior to ifosfamide therapy; consider dose reduction or discontinue if hematuria occurs. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.
GI upset, fever, anorexia, flatulence, constipation, rhinitis, rigors, back pain, rash, conjunctivitis, arthralgia, headache, inj site reactions, flushing, dizziness, pharyngitis, hyperaesthesia, flu-like symptoms, coughing; hypersensitivity reactions.
Patients taking mesna should drink at least a quart of liquid a day.
Tabs—10; Multidose vials—1, 10
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States